{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:11:58Z","timestamp":1793034718502,"version":"4.5.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.arcmed.2021.09.002","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T03:48:12Z","timestamp":1632714492000},"page":"817-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions"],"prefix":"10.1016","volume":"52","author":[{"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-1759","authenticated-orcid":false,"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4660-0450","authenticated-orcid":false,"given":"Nadia","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2021.09.002_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of Infections Due to MDR Gram-Negative Bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0002","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0082","article-title":"Tackling the threat of antimicrobial resistance: from policy to sustainable action","volume":"370","author":"Shallcross","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0005","unstructured":"WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 2017. (Accessed July 6, 2021)."},{"key":"10.1016\/j.arcmed.2021.09.002_bib0006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3390\/antibiotics9090632","article-title":"Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance","volume":"9","author":"Bassetti","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/fmb-2020-0210","article-title":"Treatment of severe infections due to metallo-beta-lactamases-producing Gram-negative bacteria","author":"Bassetti","year":"2020","journal-title":"Future Microbiol"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/jac\/dkaa478","article-title":"Impact of antibiotic timing on mortality from Gram-negative bacteraemia in an English district general hospital: the importance of getting it right every time","volume":"76","author":"Baltas","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0009","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0010","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0011","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0013","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14787210.2017.1251840","article-title":"Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections","volume":"15","author":"Bassetti","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0014","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.00009-11","article-title":"Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system","volume":"55","author":"Tumbarello","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/1469-0691.12747","article-title":"Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study","volume":"20","author":"Giannella","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0016","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.athoracsur.2016.12.041","article-title":"Healthcare-Associated Infections in Cardiac Surgery Patients With Prolonged Intensive Care Unit Stay","volume":"103","author":"Mazzeffi","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.2016.2691","article-title":"Incidence, Risk Factors, and Attributable Mortality of Secondary Infections in the Intensive Care Unit After Admission for Sepsis","volume":"315","author":"van Vught","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0018","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00134-019-05819-3","article-title":"Epidemiology of intra-abdominal infection and sepsis in critically ill patients: \"AbSeS\", a multinational observational cohort study and ESICM Trials Group Project","volume":"45","author":"Blot","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","article-title":"Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study","volume":"38","author":"Tabah","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CCM.0000000000002253","article-title":"ICU Acquisition Rate, Risk Factors, and Clinical Significance of Digestive Tract Colonization With Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis","volume":"45","author":"Detsis","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0021","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00134-019-05520-5","article-title":"Rationalizing antimicrobial therapy in the ICU: a narrative review","volume":"45","author":"Timsit","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0022","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Gutierrez-Gutierrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0023","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0024","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00134-020-05951-5","article-title":"Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0025","doi-asserted-by":"crossref","first-page":"15290","DOI":"10.1038\/s41598-019-51711-x","article-title":"L. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis","volume":"9","author":"Schmid","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0026","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0027","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0028","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0029","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0030","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.2018.12565","article-title":"Carbapenem-Sparing Therapy for Extended-Spectrum beta-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues","volume":"320","author":"Hayden","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jgar.2019.07.003","article-title":"Longitudinal analysis of the In vitro activity of ceftazidime\/avibactam versus Enterobacteriaceae, 2012\u20132016","volume":"19","author":"Ramalheira","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/1120009X.2019.1620406","article-title":"In vitro activity of ceftazidime\/avibactam against clinical isolates of ESBL-producing Enterobacteriaceae in Italy","volume":"31","author":"Viaggi","year":"2019","journal-title":"J Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0033","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0034","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/mdr.2017.0266","volume":"24","author":"Shortridge","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0035","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0036","unstructured":"ClinicalTrials.gov. Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection (MERINO III). 2020."},{"key":"10.1016\/j.arcmed.2021.09.002_bib0037","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0038","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QCO.0000000000000685","article-title":"Treatment of extended-spectrum beta-lactamases infections: what is the current role of new beta-lactams\/beta-lactamase inhibitors?","volume":"33","author":"Bassetti","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0039","doi-asserted-by":"crossref","first-page":"e00514","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0040","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0041","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-Daily Plazomicin for Complicated Urinary Tract Infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0042","first-page":"15","article-title":"Carbapenem resistance: overview of the problem and future perspectives","volume":"3","author":"Meletis","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0043","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/QCO.0000000000000314","article-title":"The management of multidrug-resistant Enterobacteriaceae","volume":"29","author":"Bassetti","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0044","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0046","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0047","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation beta-Lactam\/beta-Lactamase Inhibitor Combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0048","doi-asserted-by":"crossref","first-page":"e00883","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0049","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0050","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0051","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1093\/jac\/dky295","article-title":"Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae","volume":"73","author":"Sousa","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0052","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0053","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2378","article-title":"Imipenem-Cilastatin-Relebactam: A Novel beta-Lactam-beta-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections","volume":"40","author":"Smith","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0054","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0055","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/AAC.00633-16","article-title":"Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection","volume":"60","author":"Lucasti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0056","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0057","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0058","article-title":"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) \u00b1 Metronidazole (MTZ) Versus Meropenem (MER) \u00b1 Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria","year":"2017","journal-title":"(REVISIT)"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0059","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2018.1426745","article-title":"Cefiderocol: a novel siderophore cephalosporin","volume":"27","author":"Choi","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0061","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0062","doi-asserted-by":"crossref","first-page":"e01711","DOI":"10.1128\/AAC.01711-19","article-title":"In vitro Activity of Plazomicin Compared to Amikacin, Gentamicin, and Tobramycin against Multidrug-Resistant Aerobic Gram-Negative Bacilli","volume":"64","author":"Fleischmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0063","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0064","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0065","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0066","first-page":"1","article-title":"Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies","author":"Karaiskos","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0067","first-page":"e00212","volume":"64","author":"Lomovskaya","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/molecules24020249","article-title":"Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics","volume":"24","author":"Vaara","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0069","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0071","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0072","doi-asserted-by":"crossref","first-page":"e02291","DOI":"10.1128\/AAC.02291-19","article-title":"Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0073","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0074","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciaa003","article-title":"Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa","volume":"71","author":"Vena","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0075","doi-asserted-by":"crossref","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA Global Surveillance Program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam In vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0076","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0077","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0078","first-page":"2286","article-title":"Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0079","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","article-title":"Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program","volume":"88","author":"Lob","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.arcmed.2021.09.002_bib0080","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0081","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.1182749","article-title":"Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa","volume":"327","author":"Srinivas","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0082","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: a new antibiotic class in the pipeline","volume":"16","author":"Martin-Loeches","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0083","unstructured":"ClinicalTrials.gov. Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (PRISM-MDR). 2018."},{"key":"10.1016\/j.arcmed.2021.09.002_bib0084","unstructured":"ClinicalTrials.gov. Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas (PRISM-UDR). 2018."},{"key":"10.1016\/j.arcmed.2021.09.002_bib0085","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkaa529","article-title":"Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates","volume":"76","author":"Diez-Aguilar","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0086","doi-asserted-by":"crossref","first-page":"e00210","DOI":"10.1128\/AAC.00210-21","article-title":"In vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa","volume":"65","author":"Lomovskaya","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0087","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11096-020-01089-y","article-title":"Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents","volume":"42","author":"Provenzani","year":"2020","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0088","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14656566.2020.1817386","article-title":"Therapeutic options for difficult-to-treat Acinetobacter baumannii infections: a 2020 perspective","volume":"22","author":"Bassetti","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0089","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrmicro.2017.148","article-title":"Uncovering the mechanisms of Acinetobacter baumannii virulence","volume":"16","author":"Harding","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4068\/cmj.2014.50.2.37","article-title":"Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections","volume":"50","author":"Kim","year":"2014","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0091","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0092","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4103\/0253-7613.150383","article-title":"Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis","volume":"47","author":"Balkan","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0093","first-page":"550","article-title":"Drug-induced acute kidney injury: diverse mechanisms of tubular injury","volume":"25","author":"Perazella","year":"2019","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0094","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1378\/chest.128.2.545","article-title":"Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia","volume":"128","author":"Panidis","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0096","doi-asserted-by":"crossref","first-page":"e01110","DOI":"10.1128\/AAC.01110-18","article-title":"New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections","volume":"63","author":"Isler","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0097","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/microorganisms7060159","article-title":"The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of","volume":"7","author":"Fragkou","year":"2019","journal-title":"Clinical Evidence. Microorganisms"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0098","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0099","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/cc13942","article-title":"High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can","volume":"18","author":"Garnacho-Montero","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0100","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8395268","article-title":"Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study","volume":"2016","author":"Wu","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0101","unstructured":"ClinicalTrials.gov. Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK). 2019."},{"key":"10.1016\/j.arcmed.2021.09.002_bib0102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02534-17","article-title":"beta-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance","volume":"62","author":"Jacobs","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0103","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented Renal Clearance in Critically Ill Patients: A Systematic Review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0104","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0105","doi-asserted-by":"crossref","first-page":"330","DOI":"10.21037\/atm.2016.09.02","article-title":"Current understanding in source control management in septic shock patients: a review","volume":"4","author":"Lagunes","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.arcmed.2021.09.002_bib0106","article-title":"How to manage KPC infections","volume":"7","author":"Bassetti","year":"2020","journal-title":"Ther Adv Infect Dis"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:51:33Z","timestamp":1759261893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440921001740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":106,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0188440921001740"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.09.002","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS).","name":"copyright","label":"Copyright"}]}}